Intercept Pharmaceuticals ICPT
$ 19.0
0.0%
Quarterly report 2023-Q3
added 11-06-2023
Country |
USA |
IPO year |
2012 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Dr. Mark Pruzanski |
Employees in the company |
583 |
Shares |
33.8 M |
Market Cap[1] |
$ 643 M |
EBITDA (LTM) |
$ -80.6 M |
P/E (LTM) |
2.79 |
P/S (LTM) |
2.02 |
EPS (LTM) |
6.82 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.